On September 23, Ionis Pharmaceuticals declined 5.05% in regular trading, trading at $43.42/share, with turnover of $33.59 million. Despite a flurry of positive clinical data releases, pre-market gains were quickly erased as selling pressure resumed.
On the news front, the company announced that sefaxersen, developed in partnership with Roche, met the primary endpoint in the Phase 3 IMAgINATION trial for primary IgA nephropathy, demonstrating statistically significant reduction in proteinuria at week 37. Additionally, ulefnersen, co-developed with Otsuka Pharmaceutical, achieved its primary endpoint in the Phase 3 Fusion study for FUS-ALS, significantly improving survival and function. The company also recently secured FDA approval for zilganersen to treat Alexander disease.
However, the market reaction remained subdued. The earlier failure of eplontersen in the Phase 3 ATTR cardiomyopathy trial with AstraZeneca in July continues to weigh heavily on investor confidence. Compounding the pressure, Bank of America cut its target price to $91 and TD Cowen lowered its target to $94 from $108. The stock has now fallen more than 49% from its 52-week high of $86.74, reflecting persistent skepticism that near-term pipeline successes can compensate for core cardiovascular franchise setbacks.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments